MiNK Therapeutics is a clinical-stage biopharmaceutical company pioneering the discovery, development, and commercialization of allogeneic invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. MiNK is advancing a pipeline of both native and next-generation engineered iNKT programs, with a platform designed to facilitate scalable and reproducible manufacturing for off-the-shelf delivery. The company is headquartered in New York, NY.
Company profile
Ticker
INKT
Exchange
Website
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
AMGEN • Gilead Sciences • Biogen • Qiagen • Moderna • BioNTech SE • Exelixis • Sana Biotechnology • Bio-Techne • Ginkgo Bioworks ...
Former names
AgenTus Therapeutics, Inc., AgenTus Therapeutics, Inc.
SEC CIK
Corporate docs
Subsidiaries
AgenTus Therapeutics Limited • AgenTus Therapeutics SA ...
INKT stock data
Latest filings (excl ownership)
EFFECT
Notice of effectiveness
9 Nov 22
CORRESP
Correspondence with SEC
7 Nov 22
UPLOAD
Letter from SEC
7 Nov 22
S-3
Shelf registration
3 Nov 22
8-K
MiNK Therapeutics Reports Corporate Update and Third Quarter 2022 Financial Results
3 Nov 22
10-Q
2022 Q3
Quarterly report
3 Nov 22
10-Q
2022 Q2
Quarterly report
15 Aug 22
8-K
MiNK Therapeutics Reports Corporate Update and Second Quarter 2022 Financial Results
9 Aug 22
8-K
Entry into a Material Definitive Agreement
5 Aug 22
S-8
Registration of securities for employees
15 Jul 22
Transcripts
Financial summary
| Quarter (USD) | Sep 22 | Jun 22 | Mar 22 | Dec 21 | |
|---|---|---|---|---|---|
| Revenue | |||||
| Cost of revenue | |||||
| Operating income | |||||
| Operating margin | |||||
| Net income | |||||
| Net profit margin | |||||
| Cash on hand | |||||
| Change in cash | |||||
| Diluted EPS |
| Annual (USD) | Dec 21 | |
|---|---|---|
| Revenue | ||
| Cost of revenue | ||
| Operating income | ||
| Operating margin | ||
| Net income | ||
| Net profit margin | ||
| Cash on hand | ||
| Change in cash | ||
| Diluted EPS |
| Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
|---|---|---|---|---|---|---|
| Cash on hand (at last report) | 24.16 mm | 24.16 mm | 24.16 mm | 24.16 mm | 24.16 mm | |
| Cash burn (monthly) | 1.90 mm | (no burn) | 2.66 mm | 2.45 mm | 349.71 k | |
| Cash used (since last report) | 8.01 mm | n/a | 11.24 mm | 10.35 mm | 1.48 mm | |
| Cash remaining | 16.15 mm | n/a | 12.91 mm | 13.80 mm | 22.68 mm | |
| Runway (months of cash) | 8.5 | n/a | 4.9 | 5.6 | 64.9 | |
Institutional ownership, Q2 2022
79.0% owned by funds/institutions
| 13F holders | Current |
|---|---|
| Total holders | 14 |
| Opened positions | 1 |
| Closed positions | 13 |
| Increased positions | 2 |
| Reduced positions | 8 |
| 13F shares | Current |
|---|---|
| Total value | 319.13 mm |
| Total shares | 26.69 mm |
| Total puts | 0.00 |
| Total calls | 0.00 |
| Total put/call ratio | – |
| Largest owners | Shares | Value |
|---|---|---|
| AGEN Agenus | 26.33 mm | $318.63 mm |
| Artal | 289.59 k | $408.00 k |
| Bridgeway Capital Management | 35.50 k | $50.00 k |
| Geode Capital Management | 23.18 k | $32.00 k |
| BLK Blackrock | 6.64 k | $10.00 k |
| Tower Research Capital | 1.10 k | $2.00 k |
| MS Morgan Stanley | 463.00 | $1.00 k |
| FMR | 374.00 | $1.00 k |
| UBS UBS Group AG - Registered Shares | 258.00 | $0.00 |
| JPM JPMorgan Chase & Co. | 247.00 | $0.00 |
Recent insider trades
| Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
|---|---|---|---|---|---|---|---|---|---|---|
| 16 Jan 23 | Armen Garo H | Stock Option Common Stock | Grant | Acquire A | No | No | 2.36 | 200,000 | 472.00 k | 200,000 |
| 9 Jan 23 | Buell Jennifer | Common Stock | Grant | Acquire A | No | No | 2.32 | 171,990 | 399.02 k | 380,715 |
| 9 Jan 23 | Buell Jennifer | Stock Option Common Stock | Grant | Acquire A | No | No | 2.32 | 500,000 | 1.16 mm | 500,000 |
| 9 Jan 23 | Dijk Marcus Antonius van | Stock Option Common Stock | Grant | Acquire A | No | No | 2.32 | 15,000 | 34.80 k | 15,000 |
| 9 Jan 23 | Dijk Marcus Antonius van | Common Stock | Payment of exercise | Dispose F | No | No | 2.32 | 24,265 | 56.29 k | 27,363 |
| 9 Jan 23 | Dijk Marcus Antonius van | Common Stock | Grant | Acquire A | No | No | 2.32 | 51,628 | 119.78 k | 51,628 |
| 1 Dec 22 | Peter Behner | Common Stock | Grant | Acquire A | No | No | 2.61 | 5,891 | 15.38 k | 17,628 |